Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 APR 13 ... was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, ...
2009 FEB 2 ... anticancer agents include temsirolimus (CCI-779), everolimus (RAD-001), and deforolimus (AP23573). These agents have demonstrated antiproliferative activity against a diverse range of ...
2007 NOV 12 ... where he led chemistry campaigns which successfully advanced the mTOR inhibitor AP23573 (recently partnered with Merck) and the second-generation Src/Abl kinase inhibitor ...
2007 JUL 23 ... that they have entered into a global collaboration to jointly develop and commercialize AP23573, ARIAD's novel mTOR inhibitor, for use in cancer. It is expected that...
2007 JUL 10 ... Protocol Assessment on the design and endpoints for its Phase 3 pivotal trial of oral AP23573, its novel mTOR inhibitor, in metastatic sarcoma. Based on the FDA's response, the ...
2008 JUN 2 ... "Deforolimus trial 106 - A Phase 1 trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669)," will be given by Dr. Mita at 1:15 pm (CDT) on Saturday, May 31, 2008, ...
2008 MAR 24 ... Currently, the mTOR inhibitor rapamycin and its analogues (CCI-779, RAD001, AP23573), which induce cell-cycle arrest in the G(1) phase, are being evaluated in cancer ...
2007 SEP 3 ... development programs for ARIAD's lead product candidates - its novel mTOR inhibitor, AP23573, and its novel multi-targeted kinase inhibitor, AP24534 and will establish a medical ...
2008 MAY 12 ... pharmacokinetics, and pharmacodynamics of deforolimus ( previously known as AP23573; MK-8669), a nonprodrug rapamycin analog, in patients with advanced solid malignancies. ...
2007 AUG 22 ... Pharmaceuticals, Inc. (NASDAQ: ARIA) announced additional positive efficacy data on AP23573 - its novel mTOR inhibitor - from further analysis of its ongoing Phase 2 trial of...
2007 SEP 11 ... development programs for ARIAD's lead product candidates - its novel mTOR inhibitor, AP23573, and its novel multi-targeted kinase inhibitor, AP24534 and will establish a medical ...
2007 SEP 25 ... Protocol Assessment on the design and endpoints for its Phase 3 pivotal trial of oral AP23573, its novel mTOR inhibitor, in metastatic sarcoma. Based on the FDA's response, the ...
2007 AUG 14 ... Inc.
Report 1: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that AP23573 - its novel mTOR inhibitor - demonstrated efficacy and was well tolerated as a single ...
2007 AUG 14 ... Pharmaceuticals, Inc. (NASDAQ: ARIA) announced additional positive efficacy data on AP23573 - its novel mTOR inhibitor - from further analysis of its ongoing Phase 2 trial of...
2008 FEB 11 ... CI-1040 or PD0325901, in combination with the mTOR inhibitor, rapamycin, or its analogue AP23573, exhibited dose-dependent synergism in human lung cancer cell lines that was associated ...
2007 SEP 24 ... "Currently, the mTOR inhibitor rapamycin and its derivatives CCI-779, RAD001, and AP23573 are being evaluated in cancer clinical trials. To date, clinical results have shown good ...
2008 APR 14 ... report.
"Several inhibitors of mTOR are in clinical trials, including AP23573, which is being tested on metastatic sarcomas and other tumors. We hypothesized that a ...
